Respiratory
Tract Infections Global Clinical Trials Review, H1, 2018, a clinical trial report
by GlobalData gives an overview of clinical trials scenario for respiratory
tract infections. It contains information regarding trial numbers, average
enrolment in top countries, region-wise and country-wise (G7 & E7) trials
coverage, trial phase, status and prominent drugs for in progress trials. It
also contains details of unaccomplished trials and trial enrolment trend seen
in last five years. Thus, giving a better understanding to the stakeholders
regarding trial progresses, market opportunities and market growth.
Respiratory
tract infections are infectious diseases caused in the respiratory tract. It is
one of the most prevalent and most variable infections occurring. These
infections are generally classified as Upper respiratory tract and lower
respiratory tract infections. Upper respiratory tract infections (URTI) are
less severe. Rhinitis, sinusitis, tonsillitis, laryngitis, common cold, etc.
are examples of these infection. Lower respiratory infections are more serious
conditions like pneumonia and bronchitis. Respiratory tract infections are
reason for more than half of the total registered antibiotic prescriptions.
The fact
that respiratory tract infections occur so commonly -especially the upper
respiratory tract infection, that it has created a problem for the effective
treatment of the same. In many cases antibiotics are prescribed even if the
symptoms are mild. Many patients take antibiotics that are self-administered.
This significantly increases the drug resistance of the microorganism causing
the infection. Also, experts believe that while most of the respiratory tract
infections are cured through antimicrobial drugs; there are a few infections
that are caused by respiratory virus instead of bacteria and in such cases
antibiotics are not to be prescribed. If such cases not examined properly, can
lead to antibiotic abuse. Respiratory tract infections as a whole, contains a
huge portfolio of clinical diseases. There are many factors responsible for the
variation in medical cases. These are: patient demographics, epidemiology,
local surrounding factors, and access as well as amount of exposure to
antimicrobial therapy. Hence, there is a worldwide need for new and effective
treatments of such infections.
The global
clinical trials market is on rise and with increasing global demand for
effective drugs and therapies, the growth is anticipated to continue for the
next decade. The main drivers of this potential growth will be technological
advancements, globalization, diversity in medical profiles, population,
economic developments and favourable business regulations and policies. Apart
from this there is increase in the funding and investments from private
entities. A market shift might be the future, as companies are focusing on the
emerging countries for their potential markets and business expansions. Also,
the new- generation technologies are now helping the small and mid- size firms
and research institutes to have access to technology, data and research
platforms, that were earlier available to only the big players.
Companies
involved in the clinical trials for respiratory tract infections and covered in
the report are: GlaxoSmithKline Plc, Novartis AG, Pfizer Inc, Sanofi, Reckitt
Benckiser Group Plc, Venus Remedies Ltd,
Abbott Laboratories, NPF Materia Medica Holding, Syneos Health Inc, Sun
Pharmaceutical Industries Ltd.
To
know more, click on the link below:
Related Reports:-
+91-9015378249
